In the new study, patients diagnosed with the three main types of bile duct cancer (intrahepatic, perihilar or distal ...

Across patients with high-risk disease, median OS was significantly improved for the 4 patients who received an IDH1 inhibitor, either ivosidenib or olutasidenib, compared with the 28 patients who ...

One or more of the following drugs will also be offered depending on the genetic profile of the tumour: futibatinib, ivosidenib, zanidatamab, trastuzumab, neratinib, encorafenib and binimetinib.

One or more of the following drugs will also be offered depending on the genetic profile of the tumour: futibatinib, ivosidenib, zanidatamab, trastuzumab, neratinib, encorafenib and binimetinib.

The latter brought in acute myeloid leukaemia (AML) and cholangiocarcinoma therapy Tibsovo (ivosidenib), which was approved as a first-line therapy for AML last year in combination with Bristol ...

bringing the Bristol Myers Squibb-partnered Tibsovo (ivosidenib) for IDH1-mutant acute myeloid leukaemia to the US market. It also shares commercial rights to BMS’ Idhifa (enasidenib), also for ...

Tibsovo is used in some adults to treat certain types of cancers, such as: Tibsovo comes as a tablet that you swallow, and its active ingredient is ivosidenib. (An active ingredient is what makes ...

Ivosidenib is under clinical development by Les Laboratoires Servier and currently in Phase III for Chondrosarcoma. According to GlobalData, Phase III drugs for Chondrosarcoma does not have sufficient ...